A5030376299- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- RNA modifications and cancer
- Lymphoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chromatin Remodeling and Cancer
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Research and Treatments
- Advanced Breast Cancer Therapies
- Head and Neck Cancer Studies
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
National Clinical Research
2019-2025
Beijing Information Science & Technology University
2025
Peking Union Medical College Hospital
2010-2023
Soochow University
2023
Soochow University
2023
The First Hospital of Changsha
2023
Cancer Hospital of Chinese Academy of Medical Sciences
2021-2023
Second Affiliated Hospital of Soochow University
2023
Academy of Medical Sciences
2018-2021
Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Patients Methods Pyrotinib was administered continuously, orally, once per day to who did not have prior exposure tyrosine kinase inhibitors HER2. Planned dose escalation 80, 160, 240, 320, 400, 480 mg. For...
Abstract Background Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into mechanisms driving resistance to is necessary address restricted options and survival advantages that are compromised by patients with EGFR-mutated lung adenocarcinoma (LUAD). Methods Spatial transcriptomic proteomic analyses were utilized investigate of resistance. Co-IP, MS, RNA-seq, ChIP-seq, RIP-seq, ATAC-seq performed cell lines...
ABSTRACT Background The clinical implications of different EML4‐ALK fusion variants remain poorly elucidated in the era second‐generation ALK inhibitors. Methods This was a retrospective cohort study, wherein patients diagnosed with locally advanced or metastatic non‐small cell lung cancer harboring were stratified into two cohorts based on their first‐line treatment: Cohort 1 received alectinib, while 2 crizotinib. Statistical analysis employed to investigate impact and TP53 status efficacy...
Abstract Purpose: This phase I study assessed the safety, tolerability, MTD, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in combination with capecitabine patients HER2-positive metastatic breast cancer (MBC). Patients Methods: received oral pyrotinib 160 mg, 240 320 or 400 mg once daily continually plus 1,000 mg/m2 twice on days 1 to 14 a 21-day cycle. Pharmacokinetic blood samples were collected 14. Next-generation...
Most lung cancer patients are diagnosed after the onset of symptoms. However, whether symptoms were independently associated with diagnosis is unknown, especially in Chinese population.
Osimertinib, a third-generation epidermal growth factor receptor tyrosine-kinase inhibitor (EGFR-TKI), has demonstrated substantial clinical benefit in patients with non-small-cell lung cancer (NSCLC) who were resistant to early-generation EGFR-TKIs and had acquired T790M mutation. The aim of our study was identify the mechanisms underlying resistance osimertinib correlate them outcomes.We retrospectively analyzed advanced NSCLC received for T790M-mutated prior between March 1, 2017 December...
Abstract Background Treatment options for Chinese patients with locally advanced or metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line chemotherapy are limited. This study (ORIENT‐3) aimed to evaluate the efficacy and safety sintilimab versus docetaxel as second‐line treatment in sqNSCLC. Methods ORIENT‐3 was an open‐label, multicenter, randomized controlled phase 3 trial that recruited stage IIIB/IIIC/IV sqNSCLC platinum‐based chemotherapy. Patients...
Abstract Background Central nervous system (CNS) metastases in patients with ALK-positive non-small cell lung cancer (NSCLC) are a cause of substantial morbidity and mortality. Although alectinib had demonstrated promising intracranial efficacy several clinical trials, data were limited on its CNS activity real-world settings. Methods In this retrospective study, NSCLC brain (BM) or leptomeningeal (LM) from six hospitals China divided into three cohorts based the treatment history before...
There have been no comprehensive large-scale studies that evaluated the benefits of chemotherapy-based regimens in addressing HER2-altered advanced non-small-cell lung cancer (NSCLC) a first-line setting. Data on HER2 alteration subtypes and concomitant alterations are also limited. Accordingly, our retrospective, real-world POLISH study assesses efficacy chemotherapy alone (C) as well combinations with immune checkpoint inhibitors (C + I) or angiogenesis A) for NSCLC; molecular features...
Abstract Background Although targeted agents have been gradually applied in the treatment of HER2- mutated non-small cell lung cancer (NSCLC) recent years, patients’ therapeutic demands are far from being met. PATHER2 was first phase 2 trial to explore efficacy and safety HER2 -targeted tyrosine kinase inhibitor (TKI) pyrotinib plus antiangiogenic agent apatinib previously treated -altered metastatic NSCLC patients. Methods -mutated or -amplified patients who had failed at least first-line...
Betulinic acid is a pentacyclic plant compound obtained from the bark of white birch trees and has been demonstrated to exhibit notable pharmacological properties. In present study, anticancer potential betulinic on paclitaxel-resistant lung cancer cell line (H460) was evaluated. Cell viability evaluated by an MTT assay, clonogenic assay performed assess effects colony formation. DAPI staining using fluorescence microscopy flow cytometry were employed evaluate apoptosis. The cycle...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become important treatment options for non-small cell lung cancer (NSCLC) patients with EGFR sensitive mutation. However, the detection of driver mutation is impeded by lack adequate tumor tissues, histopathological type, long period, and heterogeneity a tumor. Therefore, it necessary to develop more convenient method guide clinical use EGFR-TKI. Circular RNAs (circRNAs) are characterized as closed structure...
Background: Programmed cell death protein 1 (PD1) inhibitors have revolutionized cancer therapy, yet many patients fail to respond.Thus, the identification of accurate predictive biomarkers therapy response will improve clinical benefit anti-PD1 therapy.Method: We assessed baseline serological autoantibody (AAb) profile against ~2300 proteins in 10 samples and ~4600 35 with alveolar soft part sarcoma (ASPS), non-small-cell lung (NSCLC) lymphoma using Nucleic Acid Programmable Protein Arrays...
Histologic transformation of non-small cell lung cancer (NSCLC) to small (SCLC) is a rare mechanism acquired resistance epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors. However, the SCLC has also been observed in non.mutant NSCLC. In these cases, whether initially co-exists with NSCLC or originates from initial remains be determined.Whole exome sequencing was performed on 10 samples 5 patients adenocarcinoma (LUAD), main subtype Somatic mutations and copy number...
Abstract Purpose After progression to immunotherapy, the standard of care for non-small cell lung cancer (NSCLC) was limited. Administration same or different immune checkpoint inhibitors (i.e., ICI rechallenge) may serve as a novel option. The present study aimed evaluate efficacy rechallenge NSCLC and explore prognostic factors. Methods In this retrospective cohort study, data advanced metastatic patients rechallenged with at Cancer Hospital, Chinese Academy Medical Sciences, Peking Union...
Background Synergistic anti-tumor effects were observed in vivo and vitro when immune checkpoint inhibitors (ICIs) combined with denosumab. However, the clinical benefit safety of this synergy have not been adequately evaluated non-small cell lung cancer (NSCLC). Methods Consecutive charts NSCLC patients bone metastases between December 2020 2021 Chinese National Cancer Center reviewed. The entire cohort was divided into one experimental group (denosumab + ICIs [DI]) three control groups...
Small-cell lung cancer (SCLC) is generally considered a 'homogenous' disease, with little documented inter-tumor heterogeneity in treatment guidance or prognosis evaluation. The precise identification of clinically relevant molecular subtypes remains incomplete and their translation into clinical practice limited. In this retrospective cohort study, we comprehensively characterized the immune microenvironment SCLC by integrating transcriptional protein profiling...